# US 2020/0138956 A1 · Compositions for drug administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138956 A1
- Document ID: US20200138956A1
- Status: Published application
- Kind: A1
- Application number: 16/678,347
- Filed: 2019-11-08
- Published: 2020-05-07
- Earliest claimed: 2018-02-06
- Assignees: Aegis Therapeutics, LLC
- Applicants: Aegis Therapeutics, LLC
- Inventors: Edward T. Maggio
- Web page: https://patentgrep.com/patent/US20200138956A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a) epinephrine; and
b) an alkylglycoside.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the alkylglycoside has an alkyl chain including between 8 to 20 carbons.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the alkylglycoside is selected from the group consisting of undecyl maltoside, dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, and sucrose mono-tetradecanoate.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the alkylglycoside is dodecyl-beta-D-maltoside.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the alkylglycoside concentration is between about 0.001% and 10.0% (w/v).

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the alkylglycoside concentration is between about 0.05% and 0.5% (w/v).

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition further comprises a membrane penetration-enhancing agent.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the membrane penetration-enhancing agent is a surfactant, a bile salt, a phospholipid, an alcohol, an enamine, a long-chain amphipathic molecule, a small hydrophobic molecule, sodium or a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin, a medium-chain fatty acid, a chelating agent, an amino acid or salt thereof, an enzyme or combination thereof.

### Claim 9 (depends on 7)

The pharmaceutical composition of claim 7, wherein the membrane penetration-enhancing agent is selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, wherein the membrane penetration-enhancing agent is benzalkonium chloride, EDTA, or a combination thereof.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition provides a Cmax for the epinephrine in a subject that is about 2 fold or greater as compared to administration without alkylglycoside.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition provides a Tmax for the epinephrine in a subject that is about 2 fold or less as compared to administration without alkylglycoside.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition provides a Tmax for the epinephrine of about 0.3 hours or less in a subject.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition has a pH of about 2.0 to 5.0.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is formulated for administration into the circulatory system of a subject via the intra-muscular, oral, ocular, intranasal, nasolacrimal, inhalation, pulmonary, sublingual, buccal, or CSF administration route.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is a liquid formulated for intranasal delivery.

### Claim 17

A method of increasing the bioavailability of epinephrine in a subject comprising administering to a subject a composition comprising epinephrine and an alkylglycoside, thereby increasing the bioavailability of the epinephrine in the subject.

### Claim 18 (depends on 17)

The method of claim 17, wherein the alkylglycoside has an alkyl chain including between 8 to 20 carbons.

### Claim 19 (depends on 18)

The method of claim 18, wherein the alkylglycoside is selected from the group consisting of undecyl maltoside, dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, and sucrose mono-tetradecanoate.

### Claim 20 (depends on 19)

The method of claim 19, wherein the alkylglycoside is dodecyl-beta-D-maltoside.

### Claim 21 (depends on 16)

The method of claim 16, wherein the alkylglycoside concentration is between about 0.001% and 10.0% (w/v).

### Claim 22 (depends on 21)

The method of claim 21, wherein the alkylglycoside concentration is between about 0.05% and 0.5% (w/v).

### Claim 23 (depends on 17)

The method of claim 17, wherein the composition further comprises a membrane penetration-enhancing agent.

### Claim 24 (depends on 23)

The method of claim 23, wherein the membrane penetration-enhancing agent is a surfactant, a bile salt, a phospholipid, an alcohol, an enamine, a long-chain amphipathic molecule, a small hydrophobic molecule, sodium or a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin, a medium-chain fatty acid, a chelating agent, an amino acid or salt thereof, an enzyme or combination thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the membrane penetration-enhancing agent is selected from the group consisting of citric acid, sodium citrate, propylene glycol, glycerin, ascorbic acid, sodium metabisulfite, ethylenediaminetetraacetic acid (EDTA) disodium, benzalkonium chloride, sodium hydroxide, and combinations thereof.

### Claim 26 (depends on 23)

The method of claim 23, wherein the membrane penetration-enhancing agent is benzalkonium chloride, EDTA, or a combination thereof.

### Claim 27 (depends on 17)

The method of claim 17, wherein the composition provides a Cmax for the epinephrine in the subject that is about 2 fold or greater as compared to administration without alkylglycoside.

### Claim 28 (depends on 17)

The method of claim 17, wherein the composition provides a Tmax for the epinephrine in the subject that is about 2 fold or less as compared to administration without alkylglycoside.

### Claim 29 (depends on 17)

The method of claim 17, wherein the composition provides a Tmax for the epinephrine of about 0.3 hours or less in the subject.

### Claim 30 (depends on 17)

The method of claim 17, wherein the composition has a pH of about 2.0 to 5.0.

### Claim 31 (depends on 17)

The method of claim 17, wherein the composition is administered into the circulatory system of the subject via the intra-muscular, oral, ocular, intranasal, nasolacrimal, inhalation, pulmonary, sublingual, buccal, or CSF administration route.

### Claim 32 (depends on 17)

The method of claim 17, wherein the composition is a liquid composition administered intranasally.
